Circulation, ISSN 0009-7322, 01/2018, Volume 137, Issue 4, pp. 323 - 334
Background: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that significantly reduces the composite of cardiovascular death, nonfatal myocardial...
clinical trial | DESIGN | secondary prevention | RATIONALE | SAFETY | canagliflozin | DISEASE | primary prevention | diabetes mellitus | PLACEBO-CONTROLLED TRIAL | OUTCOMES | BASE-LINE CHARACTERISTICS | CARDIAC & CARDIOVASCULAR SYSTEMS | PERIPHERAL VASCULAR DISEASE | Type 2 diabetes | Research | Cardiovascular diseases | Drug therapy | Risk factors | 10021 | Original s
clinical trial | DESIGN | secondary prevention | RATIONALE | SAFETY | canagliflozin | DISEASE | primary prevention | diabetes mellitus | PLACEBO-CONTROLLED TRIAL | OUTCOMES | BASE-LINE CHARACTERISTICS | CARDIAC & CARDIOVASCULAR SYSTEMS | PERIPHERAL VASCULAR DISEASE | Type 2 diabetes | Research | Cardiovascular diseases | Drug therapy | Risk factors | 10021 | Original s
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 07/2018, Volume 38, Issue 7, pp. 1644 - 1655
OBJECTIVE—Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) and statins are known to lower plasma LDL (low-density lipoprotein)-cholesterol...
leucine | 10071 | Clinical and Population Studies | 10021 | mass spectrometry | fasting | 10034 | triglycerides | 10036 | 10058 | lipoproteins
leucine | 10071 | Clinical and Population Studies | 10021 | mass spectrometry | fasting | 10034 | triglycerides | 10036 | 10058 | lipoproteins
Journal Article
Stroke, ISSN 0039-2499, 11/2019, Volume 50, Issue 11, pp. 3064 - 3071
BACKGROUND AND PURPOSE—Pilot trials suggest that glyceryl trinitrate (GTN; nitroglycerin) may improve outcome when administered early after stroke onset....
blood pressure | nitroglycerin | Original Contributions | 10173 | allied health personnel | 10110 | 10176 | 10021 | 10177 | humans | ambulances
blood pressure | nitroglycerin | Original Contributions | 10173 | allied health personnel | 10110 | 10176 | 10021 | 10177 | humans | ambulances
Journal Article
Circulation, ISSN 0009-7322, 12/2017, Volume 136, Issue 24, pp. 2311 - 2321
BACKGROUND:Endovascular treatment with mechanical thrombectomy (MT) is beneficial for patients with acute stroke suffering a large-vessel occlusion, although...
emergency medical services | stent retriever | systems of care | endovascular treatment | ischemic stroke | INTRAVENOUS T-PA | CARDIAC & CARDIOVASCULAR SYSTEMS | QUALITY | RANDOMIZED CONTROLLED-TRIAL | MECHANICAL THROMBECTOMY | CARE | ENDOVASCULAR THERAPY | HEART | IMPROVEMENT | PERIPHERAL VASCULAR DISEASE | GUIDELINES-STROKE | CLINICAL-OUTCOMES | Prospective Studies | Ischemia - epidemiology | Humans | Endovascular Procedures | Treatment Outcome | Ischemia - mortality | Stroke - surgery | Thrombectomy | Hospitals | Time Factors | Survival Analysis | Ischemia - surgery | Registries | Stroke - epidemiology | Patient Transfer - statistics & numerical data | Stroke - mortality | 10021 | 10178 | Original s
emergency medical services | stent retriever | systems of care | endovascular treatment | ischemic stroke | INTRAVENOUS T-PA | CARDIAC & CARDIOVASCULAR SYSTEMS | QUALITY | RANDOMIZED CONTROLLED-TRIAL | MECHANICAL THROMBECTOMY | CARE | ENDOVASCULAR THERAPY | HEART | IMPROVEMENT | PERIPHERAL VASCULAR DISEASE | GUIDELINES-STROKE | CLINICAL-OUTCOMES | Prospective Studies | Ischemia - epidemiology | Humans | Endovascular Procedures | Treatment Outcome | Ischemia - mortality | Stroke - surgery | Thrombectomy | Hospitals | Time Factors | Survival Analysis | Ischemia - surgery | Registries | Stroke - epidemiology | Patient Transfer - statistics & numerical data | Stroke - mortality | 10021 | 10178 | Original s
Journal Article
Circulation, ISSN 0009-7322, 02/2017, Volume 135, Issue 9, pp. 839 - 849
BACKGROUND:Small studies have suggested that high-intensity interval training (HIIT) is superior to moderate continuous training (MCT) in reversing cardiac...
heart failure | exercise | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | DISEASE | SUPERIOR | PERIPHERAL VASCULAR DISEASE | EXERCISE CAPACITY | AEROBIC EXERCISE | Echocardiography | Follow-Up Studies | Humans | Middle Aged | Heart Failure - physiopathology | Stroke Volume - physiology | Male | Heart Ventricles - diagnostic imaging | High-Intensity Interval Training | Exercise Test | Ventricular Remodeling | Exercise Tolerance | Heart Rate - physiology | Quality of Life | Female | Aged | Heart Failure - diagnosis | Heart failure | Care and treatment | Cardiac output | Health aspects | Analysis | Aerobic exercises | 10094 | 10063 | 10021 | 10101 | Original s
heart failure | exercise | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | DISEASE | SUPERIOR | PERIPHERAL VASCULAR DISEASE | EXERCISE CAPACITY | AEROBIC EXERCISE | Echocardiography | Follow-Up Studies | Humans | Middle Aged | Heart Failure - physiopathology | Stroke Volume - physiology | Male | Heart Ventricles - diagnostic imaging | High-Intensity Interval Training | Exercise Test | Ventricular Remodeling | Exercise Tolerance | Heart Rate - physiology | Quality of Life | Female | Aged | Heart Failure - diagnosis | Heart failure | Care and treatment | Cardiac output | Health aspects | Analysis | Aerobic exercises | 10094 | 10063 | 10021 | 10101 | Original s
Journal Article
Circulation, ISSN 0009-7322, 04/2016, Volume 133, Issue 15, pp. 1472 - 1483
BACKGROUND—This randomized controlled trial evaluated clinical durability of Zilver PTX, a paclitaxel-coated drug-eluting stent (DES), for femoropopliteal...
paclitaxel | drug-eluting stents | peripheral artery disease | stents | angioplasty | CARDIAC & CARDIOVASCULAR SYSTEMS | OCCLUSIVE DISEASE | PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY | POPLITEAL ARTERIES | FOLLOW-UP | LESIONS | BARE NITINOL STENT | COATED BALLOON | SUPERFICIAL FEMORAL-ARTERY | BALLOON ANGIOPLASTY | PERIPHERAL VASCULAR DISEASE | QUALITY-OF-LIFE | Recurrence | Follow-Up Studies | Ticlopidine - therapeutic use | Angioplasty | Humans | Middle Aged | Male | Popliteal Artery - drug effects | Adult | Female | Aspirin - therapeutic use | Intermittent Claudication - therapy | Paclitaxel - administration & dosage | Stents | Drug-Eluting Stents | Ischemia - therapy | Anticoagulants - therapeutic use | Combined Modality Therapy | Femoral Artery - drug effects | Paclitaxel - therapeutic use | Disease Progression | Ticlopidine - analogs & derivatives | Disease-Free Survival | Arterial Occlusive Diseases - drug therapy | Clopidogrel | Ischemia - surgery | Aged | Arterial Occlusive Diseases - therapy | Equipment Failure | Vascular Patency | Transluminal angioplasty | Drug-eluting stents | Paclitaxel | Dosage and administration | Research | Comparative analysis | Peripheral vascular diseases | 10192 | 10191 | 10143 | 10021 | 10188 | Original
paclitaxel | drug-eluting stents | peripheral artery disease | stents | angioplasty | CARDIAC & CARDIOVASCULAR SYSTEMS | OCCLUSIVE DISEASE | PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY | POPLITEAL ARTERIES | FOLLOW-UP | LESIONS | BARE NITINOL STENT | COATED BALLOON | SUPERFICIAL FEMORAL-ARTERY | BALLOON ANGIOPLASTY | PERIPHERAL VASCULAR DISEASE | QUALITY-OF-LIFE | Recurrence | Follow-Up Studies | Ticlopidine - therapeutic use | Angioplasty | Humans | Middle Aged | Male | Popliteal Artery - drug effects | Adult | Female | Aspirin - therapeutic use | Intermittent Claudication - therapy | Paclitaxel - administration & dosage | Stents | Drug-Eluting Stents | Ischemia - therapy | Anticoagulants - therapeutic use | Combined Modality Therapy | Femoral Artery - drug effects | Paclitaxel - therapeutic use | Disease Progression | Ticlopidine - analogs & derivatives | Disease-Free Survival | Arterial Occlusive Diseases - drug therapy | Clopidogrel | Ischemia - surgery | Aged | Arterial Occlusive Diseases - therapy | Equipment Failure | Vascular Patency | Transluminal angioplasty | Drug-eluting stents | Paclitaxel | Dosage and administration | Research | Comparative analysis | Peripheral vascular diseases | 10192 | 10191 | 10143 | 10021 | 10188 | Original
Journal Article
7.
Full Text
Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
Circulation, ISSN 0009-7322, 01/2017, Volume 135, Issue 4, pp. 352 - 362
BACKGROUND:Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol...
PCSK9 | apoliprotein | lipoproteins | Lp(a) | LDL receptor | low-density lipoprotein | CONTROLLED-TRIAL | FAMILIAL HYPERCHOLESTEROLEMIA | CARDIAC & CARDIOVASCULAR SYSTEMS | CARDIOVASCULAR EVENTS | LOW-DENSITY-LIPOPROTEIN | PLASMA LIPOPROTEIN(A) | SUBTILISIN/KEXIN TYPE 9 | VERY-LOW-DENSITY | APOLIPOPROTEIN-B | LDL CHOLESTEROL | PERIPHERAL VASCULAR DISEASE | TYPE-2 DIABETES-MELLITUS | Young Adult | Proprotein Convertase 9 - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Humans | Lipoproteins, VLDL - metabolism | Middle Aged | Adolescent | Adult | Female | Male | Aged | Healthy Volunteers | Proteolipids | Lipoproteins | Research | Blood lipoproteins | Low density lipoproteins | Analysis | 10195 | 10021 | 10035 | 10034 | 10036 | Original s
PCSK9 | apoliprotein | lipoproteins | Lp(a) | LDL receptor | low-density lipoprotein | CONTROLLED-TRIAL | FAMILIAL HYPERCHOLESTEROLEMIA | CARDIAC & CARDIOVASCULAR SYSTEMS | CARDIOVASCULAR EVENTS | LOW-DENSITY-LIPOPROTEIN | PLASMA LIPOPROTEIN(A) | SUBTILISIN/KEXIN TYPE 9 | VERY-LOW-DENSITY | APOLIPOPROTEIN-B | LDL CHOLESTEROL | PERIPHERAL VASCULAR DISEASE | TYPE-2 DIABETES-MELLITUS | Young Adult | Proprotein Convertase 9 - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Humans | Lipoproteins, VLDL - metabolism | Middle Aged | Adolescent | Adult | Female | Male | Aged | Healthy Volunteers | Proteolipids | Lipoproteins | Research | Blood lipoproteins | Low density lipoproteins | Analysis | 10195 | 10021 | 10035 | 10034 | 10036 | Original s
Journal Article
Circulation (Baltimore), ISSN 0009-7322, 10/2018, Volume 138, Issue 14, pp. 1387 - 1398
markdownabstractBackground: A better understanding of the factors that contribute to heterogeneous outcomes and lifetime disease burden in hypertrophic...
Genetics | Risk | Registry | Natural history | Hypertrophic Cardiomyopathy | Cardiomyopathy | Hypertrophic | Registries | hypertrophic | CARDIAC & CARDIOVASCULAR SYSTEMS | CARDIOLOGY | GUIDELINES | AMERICAN-COLLEGE | registries | natural history | PHENOTYPE ASSOCIATIONS | genetics | HEART-ASSOCIATION | SUDDEN CARDIAC DEATH | PERIPHERAL VASCULAR DISEASE | risk | MUTATIONS | cardiomyopathy | LOW CARDIOVASCULAR MORTALITY | CONTEMPORARY MANAGEMENT STRATEGIES | Care and treatment | Usage | Cardiomyopathy, Hypertrophic | Gene mutations | Genotype | Genetic aspects | Research | Diagnosis | Implantable cardioverter-defibrillators | 10090 | 10084 | 10095 | 10094 | cardiomyopathy, hypertrophic | 10021 | Original s
Genetics | Risk | Registry | Natural history | Hypertrophic Cardiomyopathy | Cardiomyopathy | Hypertrophic | Registries | hypertrophic | CARDIAC & CARDIOVASCULAR SYSTEMS | CARDIOLOGY | GUIDELINES | AMERICAN-COLLEGE | registries | natural history | PHENOTYPE ASSOCIATIONS | genetics | HEART-ASSOCIATION | SUDDEN CARDIAC DEATH | PERIPHERAL VASCULAR DISEASE | risk | MUTATIONS | cardiomyopathy | LOW CARDIOVASCULAR MORTALITY | CONTEMPORARY MANAGEMENT STRATEGIES | Care and treatment | Usage | Cardiomyopathy, Hypertrophic | Gene mutations | Genotype | Genetic aspects | Research | Diagnosis | Implantable cardioverter-defibrillators | 10090 | 10084 | 10095 | 10094 | cardiomyopathy, hypertrophic | 10021 | Original s
Journal Article
Circulation, ISSN 0009-7322, 07/2019, Volume 140, Issue 2, pp. 103 - 112
BACKGROUND:Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events,...
PCSK9 protein | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFICACY | SAFETY | alirocumab | PCSK9 | MONOCLONAL-ANTIBODY | acute coronary syndrome | REDUCING LIPIDS | mortality | cholesterol | PERIPHERAL VASCULAR DISEASE | EVOLOCUMAB | Acute coronary syndrome | Drug therapy | Patient outcomes | 10161 | 10072 | 10021 | 10034 | Original s
PCSK9 protein | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFICACY | SAFETY | alirocumab | PCSK9 | MONOCLONAL-ANTIBODY | acute coronary syndrome | REDUCING LIPIDS | mortality | cholesterol | PERIPHERAL VASCULAR DISEASE | EVOLOCUMAB | Acute coronary syndrome | Drug therapy | Patient outcomes | 10161 | 10072 | 10021 | 10034 | Original s
Journal Article
10.
Full Text
Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
Circulation Research, ISSN 0009-7330, 05/2018, Volume 122, Issue 10, pp. 1439 - 1459
Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes mellitus. Glucose-lowering agents that reduce the risk of major...
empagliflozin | heart failure | CARDIAC & CARDIOVASCULAR SYSTEMS | REDUCING BLOOD-PRESSURE | COTRANSPORTER 2 INHIBITORS | myocardial infarction | HEART-FAILURE HOSPITALIZATION | stroke | ANGIOTENSIN-CONVERTING ENZYME | PEPTIDE-1 RECEPTOR AGONISTS | BASE-LINE CHARACTERISTICS | ALL-CAUSE MORTALITY | DIPEPTIDYL PEPTIDASE-4 INHIBITORS | mortality | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | TYPE-2 DIABETES-MELLITUS | REG OUTCOME TRIAL | Treatment outcome | Proteases | Analysis | Research | Cardiovascular diseases | Drug therapy | Risk factors | 10060 | 10150 | 10161 | 10072 | 10094 | Reviews | 10099 | 10021 | 10178 | 10189 | 10058
empagliflozin | heart failure | CARDIAC & CARDIOVASCULAR SYSTEMS | REDUCING BLOOD-PRESSURE | COTRANSPORTER 2 INHIBITORS | myocardial infarction | HEART-FAILURE HOSPITALIZATION | stroke | ANGIOTENSIN-CONVERTING ENZYME | PEPTIDE-1 RECEPTOR AGONISTS | BASE-LINE CHARACTERISTICS | ALL-CAUSE MORTALITY | DIPEPTIDYL PEPTIDASE-4 INHIBITORS | mortality | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | TYPE-2 DIABETES-MELLITUS | REG OUTCOME TRIAL | Treatment outcome | Proteases | Analysis | Research | Cardiovascular diseases | Drug therapy | Risk factors | 10060 | 10150 | 10161 | 10072 | 10094 | Reviews | 10099 | 10021 | 10178 | 10189 | 10058
Journal Article
Circulation Research, ISSN 0009-7330, 2017, Volume 121, Issue 10, pp. 1192 - 1204
Rationale: Umbilical cord-derived mesenchymal stem cells (UC-MSC) are easily accessible and expanded in vitro, possess distinct properties, and improve...
Heart failure | Mesenchymal stromal cells | Cardiomyopathies | Clinical trial | Umbilical cord | clinical trial | heart failure | CARDIAC & CARDIOVASCULAR SYSTEMS | GROWTH-FACTOR GENE | mesenchymal stromal cells | DILATED CARDIOMYOPATHY | SPANISH VERSION | ENDOTHELIAL PROGENITOR CELLS | ISCHEMIC CARDIOMYOPATHY | THERAPY | DOUBLE-BLIND | CANINE HEART | PERIPHERAL VASCULAR DISEASE | umbilical cord | STROMAL CELLS | HEMATOLOGY | cardiomyopathies | BLOOD | Double-Blind Method | Umbilical Cord - transplantation | Humans | Middle Aged | Mesenchymal Stem Cells - physiology | Male | Treatment Outcome | Cell Movement - physiology | Mesenchymal Stem Cell Transplantation - methods | Heart Failure - therapy | Female | Aged | Heart Failure - diagnosis | Infusions, Intravenous | Treatment outcome | Usage | Injections, Intravenous | Safety and security measures | Magnetic resonance imaging | Analysis | Stem cells | Diagnosis | Research | 10019 | 10090 | Clinical Track | 10094 | 10052 | 10021
Heart failure | Mesenchymal stromal cells | Cardiomyopathies | Clinical trial | Umbilical cord | clinical trial | heart failure | CARDIAC & CARDIOVASCULAR SYSTEMS | GROWTH-FACTOR GENE | mesenchymal stromal cells | DILATED CARDIOMYOPATHY | SPANISH VERSION | ENDOTHELIAL PROGENITOR CELLS | ISCHEMIC CARDIOMYOPATHY | THERAPY | DOUBLE-BLIND | CANINE HEART | PERIPHERAL VASCULAR DISEASE | umbilical cord | STROMAL CELLS | HEMATOLOGY | cardiomyopathies | BLOOD | Double-Blind Method | Umbilical Cord - transplantation | Humans | Middle Aged | Mesenchymal Stem Cells - physiology | Male | Treatment Outcome | Cell Movement - physiology | Mesenchymal Stem Cell Transplantation - methods | Heart Failure - therapy | Female | Aged | Heart Failure - diagnosis | Infusions, Intravenous | Treatment outcome | Usage | Injections, Intravenous | Safety and security measures | Magnetic resonance imaging | Analysis | Stem cells | Diagnosis | Research | 10019 | 10090 | Clinical Track | 10094 | 10052 | 10021
Journal Article
Circulation, ISSN 0009-7322, 06/2017, Volume 135, Issue 23, pp. 2227 - 2236
BACKGROUND:Numerous studies have reported favorable outcomes using drug-coated balloons (DCBs) for treatment of symptomatic peripheral artery disease of the...
Peripheral artery disease | Drug-eluting balloon | Percutaneous treatment | Randomized controlled trial | Paclitaxel | SWINE MODEL | paclitaxel | CARDIAC & CARDIOVASCULAR SYSTEMS | peripheral artery disease | METAANALYSIS | drug-eluting balloon | EFFICACY | SAFETY | LESIONS | randomized controlled trial | percutaneous treatment | RESTENOSIS | PERIPHERAL VASCULAR DISEASE | NITINOL STENTS | Angioplasty - trends | Single-Blind Method | Femoral Artery - pathology | Peripheral Arterial Disease - surgery | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Coated Materials, Biocompatible - administration & dosage | Europe - epidemiology | Male | Treatment Outcome | Angioplasty - methods | Time Factors | Peripheral Arterial Disease - epidemiology | Peripheral Arterial Disease - diagnostic imaging | Female | Popliteal Artery - surgery | Aged | Popliteal Artery - pathology | Paclitaxel - administration & dosage | Angioplasty, Balloon - trends | Femoral Artery - surgery | Angioplasty, Balloon - methods | 10191 | 10193 | 10195 | 10021 | Original s
Peripheral artery disease | Drug-eluting balloon | Percutaneous treatment | Randomized controlled trial | Paclitaxel | SWINE MODEL | paclitaxel | CARDIAC & CARDIOVASCULAR SYSTEMS | peripheral artery disease | METAANALYSIS | drug-eluting balloon | EFFICACY | SAFETY | LESIONS | randomized controlled trial | percutaneous treatment | RESTENOSIS | PERIPHERAL VASCULAR DISEASE | NITINOL STENTS | Angioplasty - trends | Single-Blind Method | Femoral Artery - pathology | Peripheral Arterial Disease - surgery | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Coated Materials, Biocompatible - administration & dosage | Europe - epidemiology | Male | Treatment Outcome | Angioplasty - methods | Time Factors | Peripheral Arterial Disease - epidemiology | Peripheral Arterial Disease - diagnostic imaging | Female | Popliteal Artery - surgery | Aged | Popliteal Artery - pathology | Paclitaxel - administration & dosage | Angioplasty, Balloon - trends | Femoral Artery - surgery | Angioplasty, Balloon - methods | 10191 | 10193 | 10195 | 10021 | Original s
Journal Article
Stroke, ISSN 0039-2499, 10/2019, Volume 50, Issue 10, pp. 2668 - 2676
BACKGROUND AND PURPOSE—In infants with perinatal arterial ischemic stroke (PAIS), early prognosis of neurodevelopmental outcome is important to adequately...
developmental disabilities | neonate/newborn | BIRTH ASPHYXIA | PREDICTIVE-VALUE | stroke | hemodynamic monitoring | AMPLITUDE-INTEGRATED EEG | CLINICAL NEUROLOGY | ENCEPHALOPATHY | brain injury | FUNCTION MONITOR | FULL-TERM INFANTS | PERIPHERAL VASCULAR DISEASE | neonatal intensive care | Original Contributions | 10132 | 10176 | 10021 | 10178 | neonate | newborn
developmental disabilities | neonate/newborn | BIRTH ASPHYXIA | PREDICTIVE-VALUE | stroke | hemodynamic monitoring | AMPLITUDE-INTEGRATED EEG | CLINICAL NEUROLOGY | ENCEPHALOPATHY | brain injury | FUNCTION MONITOR | FULL-TERM INFANTS | PERIPHERAL VASCULAR DISEASE | neonatal intensive care | Original Contributions | 10132 | 10176 | 10021 | 10178 | neonate | newborn
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 11/2019, Volume 39, Issue 11, pp. 2248 - 2260
OBJECTIVE:Homozygous familial hypercholesterolemia is a rare disease usually caused by LDLR (low-density lipoprotein receptor) mutations. Homozygous familial...
proof of concept study | rare disease | TRANSMEMBRANE DOMAIN | PCSK9 | MONOCLONAL-ANTIBODY | hypercholesterolemia | mutations | INHIBITION | GENE | DOUBLE-BLIND | ANGPTL3 | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | EVOLOCUMAB | lipoproteins | AMG 145 | 10021 | 10034 | 10188 | 10014 | 10058 | Basic Sciences
proof of concept study | rare disease | TRANSMEMBRANE DOMAIN | PCSK9 | MONOCLONAL-ANTIBODY | hypercholesterolemia | mutations | INHIBITION | GENE | DOUBLE-BLIND | ANGPTL3 | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | EVOLOCUMAB | lipoproteins | AMG 145 | 10021 | 10034 | 10188 | 10014 | 10058 | Basic Sciences
Journal Article
15.
Full Text
Pregnancy-Related Acute Kidney Injury in Preeclampsia: Risk Factors and Renal Outcomes
Hypertension, ISSN 0194-911X, 11/2019, Volume 74, Issue 5, pp. 1144 - 1151
Preeclampsia is a common cause of acute kidney injury (AKI) in low- and middle-income countries, but AKI incidence in preeclampsia, its risk factors, and renal...
POPULATION | renal insufficiency | pregnancy | preeclampsia | FAILURE | GLOMERULAR-FILTRATION-RATE | RECOVERY | creatinine | DISEASE | PERIPHERAL VASCULAR DISEASE | acute kidney injury | chronic | AKI | renal insufficiency, chronic | 10021 | 10112 | Original
POPULATION | renal insufficiency | pregnancy | preeclampsia | FAILURE | GLOMERULAR-FILTRATION-RATE | RECOVERY | creatinine | DISEASE | PERIPHERAL VASCULAR DISEASE | acute kidney injury | chronic | AKI | renal insufficiency, chronic | 10021 | 10112 | Original
Journal Article